Gilead is heavily reliant on partnerships for its late-stage pipeline, including collaborations on oncology and virology candidates. This creates a need for solutions that manage complex, multi-party clinical trials, data sharing, and joint regulatory submissions.
Filing excerpt
In collaboration with Merck & Co., Inc. (“Merck”)(1), an oral combination of Merck’s islatravir and lenacapavir is being evaluated as a long-acting HIV treatment...
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
Vendors
Vendors named
sec-10kjointVentureGet every 10-K signal for Gilead and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Gilead this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/be56b72d-1870-4c29-ad59-e111943c3ed2 returns this record as JSON. POST /v1/companies/enrich returns every signal for gilead.com.
{
"signal_id": "be56b72d-1870-4c29-ad59-e111943c3ed2",
"signal_type": "sec-10k",
"signal_subtype": "jointVenture",
"detected_at": "2026-03-03T05:50:03.57+00:00",
"company": {
"name": "Gilead",
"domain": "gilead.com"
},
"data": {
"detail": "Gilead is heavily reliant on partnerships for its late-stage pipeline, including collaborations on oncology and virology candidates. This creates a need for solutions that manage complex, multi-party clinical trials, data sharing, and joint regulatory submissions.",
"metrics": {
"timeframe": "multi_year"
},
"summary": "Gilead advances pipeline through strategic collaborations with Merck, Arcellx, and Arcus.",
"excerpts": "In collaboration with Merck & Co., Inc. (“Merck”)(1), an oral combination of Merck’s islatravir and lenacapavir is being evaluated as a long-acting HIV treatment...",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm",
"filing_date": "2026-02-24",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "New entity needs",
"signal_category": "strategic",
"vendors_mentioned": [
"Merck & Co., Inc.",
"Arcellx, Inc.",
"Arcus Biosciences, Inc."
],
"technologies_mentioned": [
"CAR T-cell therapy",
"anti-TIGIT antibody",
"anti-PD-1 monoclonal antibody"
]
}
}
curl https://signals.autobound.ai/v1/signals/be56b72d-1870-4c29-ad59-e111943c3ed2 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"gilead.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.